View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Events4SC 配当と自社株買い配当金 基準チェック /064SC配当金を支払った記録がありません。主要情報n/a配当利回り-366.8%バイバック利回り総株主利回り-366.8%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updates分析記事 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.分析記事 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).お知らせ • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024お知らせ • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024お知らせ • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023分析記事 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).お知らせ • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.お知らせ • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023お知らせ • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.決済の安定と成長配当データの取得安定した配当: VSCの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: VSCの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場4SC 配当利回り対市場VSC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (VSC)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Biotechs)2.2%アナリスト予想 (VSC) (最長3年)n/a注目すべき配当: VSCは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: VSCは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: VSCの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: VSCが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/18 09:16終値2025/12/16 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋4SC AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Linda PomeroyEdison Investment ResearchMarcus WieprechtStifel, Equities Research
分析記事 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.
お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025
New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).
Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
分析記事 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).
お知らせ • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024
お知らせ • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024
お知らせ • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.
Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023
分析記事 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...
Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).
お知らせ • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.
お知らせ • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023
お知らせ • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023
Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.
Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.